### FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

	Washington	i, D.C. 20549	
<b>STATEMENT</b>	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  CARTER BRUCE L A			2. Issuer Name <b>and</b> Ticker or Trading Symbol  ENANTA PHARMACEUTICALS INC  ENTA ]						(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>CHITER BROCE E II</u>									EN		X Directo			10% Ov		
(Last)	(Fi	rst)	(Middle)									Officer below)	r (give title )		Other (s below)	specify
C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET				3. Date of Earliest Transaction (Month/Day/Year) 11/22/2013										ŕ		
			4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable						
(Street)											Lin	,	filed by One	Popo	orting Borco	,
WATER	ΓOWN M	A	02472										filed by Mor	•	Ü	
(City)	(St	ate)	(Zip)									. 0.00				
		Tab	le I - Non-De	rivativ	e Sec	curitie	s Ac	quired, D	isposed (	of, or Be	neficial	ly Owne	d			
1. Title of Security (Instr. 3)  2. Transa Date (Month/L		nsaction th/Day/Ye	Execution Date,		Code (Ins	Transaction Disposed Of (D) (Instr. 3, 4					Form: (D) or	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code V	Amount	(A) o (D)	r Price	Transac (Instr. 3	tion(s)			(Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any		Code	ransaction of ode (Instr. Derivative		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$23.4	11/22/2013		A		9,280		(1)	11/22/2023	Common Stock	9,280	\$0	9,280		D	

## Explanation of Responses:

1. Such option will become exercisable monthly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding monthly period in which a whole share equivalent is accumulated) over three years, beginning from the date of grant (November 22, 2013).

### Remarks:

/s/ Paul J. Mellett as attorneyin-fact

\*\* Signature of Reporting Person Date

12/06/2013

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.